Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Autor:	Andrew J Webb, Carly Wadle, Taylor Morrisette, Iman Ansari, Keira A. Cohen, Jeannette Bouchard, Tristan W Gore, Michael P. Veve, Sara Alosaimy, Abdalhamid M Lagnf, Michael J. Rybak, Melissa Barger, Carlos Mejia-Chew, Catessa Howard, Julie V. Philley
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	0301 basic medicine medicine.medical_specialty 030106 microbiology Mycobacterium abscessus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interquartile range Internal medicine Omadacycline medicine 030212 general & internal medicine Adverse effect Lung biology business.industry omadacycline biology.organism_classification rapidly growing nontuberculous mycobacteria Mycobacterium abscessus Infections Regimen Infectious Diseases medicine.anatomical_structure AcademicSubjects/MED00290 Oncology chemistry Nontuberculous mycobacteria Brief Reports business
Zdroj:	Open Forum Infectious Diseases
ISSN:	2328-8957
Popis:	Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070ccfab60405e0b2424dd20332fd989 http://europepmc.org/articles/PMC7890947 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.